Gilead Payables Turnover vs Free Cash Flow Per Share Analysis
GILD Stock | USD 65.42 0.15 0.23% |
Gilead Sciences financial indicator trend analysis is much more than just examining Gilead Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gilead Sciences is a good investment. Please check the relationship between Gilead Sciences Payables Turnover and its Free Cash Flow Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
Payables Turnover vs Free Cash Flow Per Share
Payables Turnover vs Free Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gilead Sciences Payables Turnover account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have weak relationship.
The correlation between Gilead Sciences' Payables Turnover and Free Cash Flow Per Share is 0.39. Overlapping area represents the amount of variation of Payables Turnover that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Gilead Sciences, assuming nothing else is changed. The correlation between historical values of Gilead Sciences' Payables Turnover and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payables Turnover of Gilead Sciences are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Payables Turnover i.e., Gilead Sciences' Payables Turnover and Free Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | 0.39 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 27.3B | 27.3B | 27.1B | 28.5B | Interest Expense | 1.0B | 935M | 944M | 534.5M |
Gilead Sciences fundamental ratios Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Short Long Term Debt Total | 24.6B | 31.4B | 26.7B | 25.2B | 25.0B | 26.2B | |
Other Current Liab | 6.5B | 7.8B | 9.4B | 8.1B | 11.3B | 11.8B | |
Total Current Liabilities | 9.8B | 11.4B | 11.6B | 11.2B | 11.3B | 11.8B | |
Total Stockholder Equity | 22.7B | 18.2B | 21.1B | 21.2B | 22.7B | 23.9B | |
Property Plant And Equipment Net | 4.5B | 5.0B | 5.1B | 5.5B | 5.3B | 5.6B | |
Net Debt | 13.0B | 25.4B | 21.4B | 19.8B | 18.9B | 19.8B | |
Retained Earnings | 19.4B | 14.4B | 16.3B | 15.7B | 16.3B | 17.1B | |
Accounts Payable | 713M | 844M | 705M | 905M | 550M | 518.2M | |
Cash | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.8B | |
Non Current Assets Total | 30.1B | 52.6B | 52.9B | 47.9B | 45.7B | 48.0B | |
Non Currrent Assets Other | 7.7B | 6.4B | 6.0B | 4.0B | 5.6B | 5.9B | |
Cash And Short Term Investments | 25.8B | 7.9B | 7.8B | 7.6B | 8.4B | 7.5B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.5B | |
Liabilities And Stockholders Equity | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Non Current Liabilities Total | 29.2B | 38.8B | 35.3B | 30.7B | 28.1B | 29.5B | |
Other Current Assets | 1.4B | 2.0B | 2.1B | 1.8B | 2.4B | 1.3B | |
Other Stockholder Equity | 3.2B | 3.9B | 4.7B | 5.5B | (16.3B) | (15.5B) | |
Total Liab | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 41.3B | |
Total Current Assets | 31.5B | 15.8B | 15.1B | 15.2B | 16.5B | 10.8B | |
Short Term Debt | 2.5B | 2.8B | 1.5B | 2.3B | 1.8B | 1.9B | |
Net Receivables | 3.6B | 4.9B | 4.5B | 4.8B | 4.7B | 2.4B | |
Property Plant And Equipment Gross | 4.5B | 5.0B | 7.0B | 7.7B | 7.8B | 8.2B | |
Accumulated Other Comprehensive Income | 85M | (60M) | 83M | 2M | 28M | 37.6M | |
Short Term Investments | 12.7B | 1.4B | 1.2B | 973M | 1.2B | 1.1B | |
Inventory | 2.1B | 3.0B | 2.7B | 2.8B | 3.4B | 3.5B | |
Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
Long Term Debt | 22.1B | 28.6B | 25.2B | 23.0B | 23.2B | 12.2B | |
Property Plant Equipment | 4.5B | 5.0B | 5.1B | 5.5B | 6.3B | 6.6B | |
Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
Noncontrolling Interest In Consolidated Entity | 125M | 19M | (5M) | (31M) | (84M) | (79.8M) | |
Retained Earnings Total Equity | 19.4B | 14.4B | 16.3B | 15.7B | 18.0B | 12.7B | |
Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3.02 | Earnings Share 4.5 | Revenue Per Share 22 | Quarterly Revenue Growth 0.053 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.